Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Nav

General Info

Email
Print

Geography

Argentina (ARG)

Austria (AUT)

Canada (CAN)

Chile (CHL)

China (CHN)

Hong Kong

Congo (COG)

Brazzaville

Costa Rica (CRI)

Czechia (CZE)

Denmark (DNK)

Germany (DEU)

Honduras (HND)

Francisco Morazán

Hungary (HUN)

Israel (ISR)

Italy (ITA)

Japan (JPN)

Malaysia (MYS)

Mexico (MEX)

Netherlands (NLD)

New Zealand (NZL)

Peru (PER)

Portugal (PRT)

Singapore (SGP)

Slovakia (SVK)

Trinidad and Tobago (TTO)

Port of Spain

United Kingdom (GBR)

United States of America (USA)

Puerto Rico

Venezuela (Bolivarian Republic of) (VEN)

View all

Time period covered

01/2001 - 12/2001

Data type

Scientific literature

Keywords

Cardiovascular and circulatory diseases, Ischemic heart disease, Blood pressure

Citation

Authors

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators

Journal

N Engl J Med

Volume

345

Issue

12

Pages

861-9

Publication year

2001

Suggested citation

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12): 861-9.

GHDx Entry last modified on: Oct 8, 2022